NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws.
On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. Biodexa disclosed that of the four patients who were enrolled in Cohort A of the study, two are now deceased, with one achieving an overall survival of 12 months and the other 13 months since the start of treatment.
Follow this news, Biodexa's stock price fell over 7% on the same day. To obtain additional information, go to:
https://zlk.com/pslra-1/biodexa-pharmaceuticals-plc-lawsuit-submission-form?prid=108788&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on accesswire.com
